This session will provide a bench to bedside review of the current stage of knowledge in the field of cardiac amyloidosis. The session will cover clinically relevant molecular insights regarding pathophysiology and potential treatment targets, clinical approach to identifying and evaluating patients with cardiac amyloid, utility and potential pitfalls of noninvasive cardiac imaging techniques in the evaluation of suspected amyloid, role of advanced heart failure therapies in patients with cardiac amyloid, current and emerging targeted therapies for transthyretin amyloidosis, and a practical review of tips for navigating challenges related to pharmacotherapy in patients with transthyretin cardiac amyloidosis.

• Describe molecular insights relevant to understanding the pathophysiology and potential treatment targets in cardiac amyloidosis, TTR Amyloidosis.
• Provide an overview of clinical clues that should raise the index of suspicion for cardiac amyloid, and the diagnostic approach, including the role of cardiac imaging and endomyocardial biopsy.
• Identify current and emerging therapeutic approaches to the care of patients with cardiac amyloidosis, TTR type